ArticleThe oncologist2011
Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.
Article in The oncologist, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 5 syntheses or guidelines pooled it, 181 citations in OpenAlex.
- Is withdrawal of antiresorptive agents necessary before and after tooth extraction? A systematic review.Clinical oral investigations · 2023Pooled it
- Interventions for managing medication-related osteonecrosis of the jaw.The Cochrane database of systematic reviews · 2022Pooled it
- Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2020Pooled it
- Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis.Journal of the American Dental Association (1939) · 2019Pooled it
- Interventions for managing medication-related osteonecrosis of the jaw.The Cochrane database of systematic reviews · 2017Pooled it
- The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study.Clinical oral investigations · 2021Trial
- Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Trial
- Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study.BioMed research international · 2020Trial
- Review
- Important learning points for setting up a dental-oncology service in Ireland.Irish journal of medical science · 2026Article
- Postoperative healing and recurrence in osteonecrosis of the jaw: influence of risk factors and surgical approach.Clinical oral investigations · 2026Article
- Efficacy and risks of drug holiday in the management of medication-related osteonecrosis of the jaw in cancer patients: a single-center retrospective study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Effect of nasogastric tube feeding on oral wound healing and oral health-related quality of life (OHRQoL) after surgery for medication-related osteonecrosis of the jaw (MRONJ).Head & face medicine · 2025Article
- Surgery with leukocyte and platelet-rich fibrin (L-PRF) vs. surgery alone for medication-related osteonecrosis of the jaw: A randomized controlled trial.Journal of clinical and experimental dentistry · 2025Article
- Clinical Effectiveness of Surgical Marginal Resection with Piezoelectric Device on Bisphosphonate-Related Osteonecrosis of the Jaws: A Retrospective Study.Journal of clinical medicine · 2025Article
- Article
- Autologous and Heterologous Minor and Major Bone Regeneration with Platelet-Derived Growth Factors.Journal of functional biomaterials · 2025Review
- Bone scintigraphy and positron emission tomography in the early diagnosis of MRONJ.Open medicine (Warsaw, Poland) · 2025Article
- Education and Communication on the Topic of Osteonecrosis of the Jaw When Taking Bone-Stabilizing Drugs.Clinical and experimental dental research · 2024Article
- Genetic Background of Medication-Related Osteonecrosis of the Jaw: Current Evidence and Future Perspectives.International journal of molecular sciences · 2024Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
purposePotentially debilitating, osteonecrosis of the jaw (ONJ) is an emerging complication of bisphosphonates. However, its effect on quality of life (QoL) is unknown. We determined the ONJ-related QoL decline in a cancer patient cohort. PATIENTS AND
methodsThirty-four cancer patients with bisphosphonate-associated ONJ completed a telephone survey (October 2007 through May 2008). The Oral Health Impact Profile 14 (OHIP) retrospectively assessed participant oral health-related QoL before and after ONJ. Standardized ONJ descriptions were developed in a multidisciplinary, iterative process and were evaluated with three frequently used preference-based QoL measurement methods on a 0 (death) to 1 (perfect health) scale: Visual Analogue Scale (VAS), Time Trade-Off (TTO), and EQ-5D.
resultsONJ significantly (p < .001) increased OHIP scores (worse QoL) for additive (3.56-16.53) and weighted (7.0-17.5) methods. Seven individual OHIP items significantly increased (Bonferroni correction p < .0035): pain, eating discomfort, self-consciousness, unsatisfactory diet, interrupted meals, irritability, and decreased life satisfaction. Mean preference-based QoL values significantly decreased (p < .001) with worsening ONJ stage (VAS, TTO, and EQ-5D): no ONJ (0.76, 0.86, 0.82), ONJ stage 1 (0.69, 0.82, 0.78), ONJ stage 2 (0.51, 0.67, 0.55), and ONJ stage 3 (0.37, 0.61, 0.32). As ONJ worsened, EQ-5D domain scores significantly increased (p < .001). Pain/discomfort and anxiety/depression contributed most to declining QoL.
conclusionsONJ significantly affects QoL, a detriment that increases with worsening ONJ. QoL impairments for ONJ stages 2 and 3 are similar to other treatment side effects that influence decision-making. Bisphosphonate-associated ONJ QoL is an important consideration for patients, clinicians, and policy makers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.